Spanish pharma market growth 8%

15 June 2008

The Spanish drug market has registered annual growth of about 8% since 2004, according to figures from IMS Health. Sales of drugs in Spain in 2007 increased 8.8% to a value of some 13.2 billion euros ($20.49 billion). Some slowing of growth is forecast for this year. New drug development has been focused in the oncology and biotechnology areas.

The oncology drug market grew 15.7% in Spain in 2007 with sales of around 1.1 billion euros, while the strongest sector was that of cardiovascular drugs with sales of 2.07 billion euros. Pfizer led the field with a market share of 6.5% followed by Sanofi-Aventis at 6.2%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight